Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oculis Holding AG (OCS) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory submissions, primarily filed as a foreign private issuer on Form 20-F and Form 6-K. These documents provide detail on Oculis’ biopharmaceutical business in ophthalmology and neuro-ophthalmology, its late-stage clinical pipeline, and its financing arrangements.
Form 6-K reports referenced in public records include unaudited condensed consolidated interim financial statements and management’s discussion and analysis for half-year and quarterly periods. Other 6-K filings describe capital-raising transactions, such as underwritten and registered direct offerings of ordinary shares made under shelf registration statements on Form F-3, as well as the suspension of an at-the-market prospectus supplement. Additional filings outline an amended and restated loan facility with a lender affiliated with BlackRock, including warrant terms linked to borrowing tranches.
These filings also incorporate press releases and corporate presentations that discuss the advancement of Privosegtor into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy, the Phase 3 DIAMOND program for OCS-01 eye drops in diabetic macular edema, and development plans for Licaminlimab in dry eye disease. Together, they document how Oculis reports clinical progress, regulatory designations such as Breakthrough Therapy and Orphan Drug status for Privosegtor, and its capital structure.
On Stock Titan, investors can review these OCS filings alongside AI-powered summaries that explain the key points of each document, highlight material financing terms, and flag updates related to clinical programs or risk disclosures. The page also links to information on equity offerings, loan covenants, and warrant arrangements that may affect existing and prospective shareholders.
Oculis Holding AG reporting persons filed an amended Schedule 13G/A stating that Beyeotech directly holds 2,436,902 Ordinary Shares, representing 4.14% of the outstanding ordinary shares based on February 13, 2026 and a reported share count of 58,932,987 Ordinary Shares.
The statement names the related filers—BVCF IV, L.P., Beyeotech, BVCF IV GP, Ltd. and Zhi Yang—and explains their ownership and control relationships, including that GP is the general partner of the Fund and Mr. Zhi Yang is sole shareholder/director of GP.
Oculis Holding AG reported a 2025 net loss of CHF 98.96m, compared with a CHF 85.78m loss in 2024, as it advanced late-stage ophthalmic drug development. Research and development expenses rose to CHF 57.1m, while general and administrative costs reached CHF 25.8m, driven mainly by clinical programs and share-based compensation.
Despite ongoing losses, Oculis strengthened its balance sheet. Cash and cash equivalents were CHF 81.33m and short-term financial assets were CHF 131.68m as of December 31, 2025, following underwritten offerings totaling CHF 178.9m in gross proceeds. Total equity increased to CHF 196.07m and total assets to CHF 235.96m, giving the company resources to fund its pipeline.
Separately, Oculis renewed its at-the-market equity program by entering into an amended and restated sales agreement with Leerink Partners tied to a new Form F-3 shelf registration. The ATM program permits offers and sales, at the company’s discretion, of ordinary shares up to an aggregate offering price of $100m through Leerink Partners as sales agent.
Oculis Holding, a late clinical-stage biopharmaceutical company focused on ophthalmic and neuro‑ophthalmic diseases, reports continued pre‑revenue investment in its pipeline, including OCS‑01 for diabetic macular edema, Licaminlimab for dry eye disease and Privosegtor for optic neuritis and related conditions.
For the year ended December 31, 2025, Oculis recorded a net loss of CHF 99.0 million, compared with CHF 85.8 million in 2024, bringing accumulated losses to CHF 384.5 million. The company held CHF 213.0 million in cash, cash equivalents and short‑term financial assets, which it believes will fund operations for at least the next twelve months. As of December 31, 2025, it had 57,984,438 ordinary shares, 2,104,906 warrants to purchase ordinary shares and 60 employees.
Oculis Holding reported a 2025 net loss of CHF 99.0 million (vs. CHF 85.8 million in 2024) as it stepped up investment in its late‑stage pipeline. Cash, cash equivalents and short‑term investments rose to CHF 213.0 million, or $268.7 million, helped by $210.0 million of equity financings in February and November 2025, giving a cash runway into 2029.
During 2025, the company obtained FDA Breakthrough Therapy designation for Privosegtor in optic neuritis and initiated the PIONEER‑1 registrational trial. Both Phase 3 DIAMOND trials of OCS‑01 in diabetic macular edema enrolled over 800 patients, with topline data expected in Q2 2026 and a possible NDA in Q4 2026 if results are positive. Oculis also launched the genotype‑based PREDICT‑1 registrational trial of Licaminlimab in dry eye disease, with topline results targeted for Q4 2026.
Oculis Holding AG filed a Form F-3 to register the resale of up to 494,259 ordinary shares by the selling securityholder. The shares are issuable upon exercise of a warrant originally issued on May 29, 2024 and amended on July 31, 2025. Oculis is not selling any securities under this prospectus and will not receive proceeds from resales; it would receive the warrant exercise price if exercised in cash.
The warrant is currently exercisable for 59,310 shares and may become exercisable for up to 494,259 shares based on draws under a three‑loan facility or a specified milestone. Exercise prices are $12.17 for 361,011 shares and $18.64 for 133,248 shares. If fully exercised for cash for the maximum shares, Oculis would receive $6,877,246.59. Shares outstanding were 52,374,811 as of September 30, 2025. The ordinary shares trade on Nasdaq and Nasdaq Iceland under the symbol OCS.
Oculis Holding AG filed a Form 6-K to furnish its unaudited financial results for the three and nine month periods ended September 30, 2025. The filing states that detailed figures and commentary are provided in attached unaudited condensed consolidated interim financial statements, a management discussion and analysis, and a press release. It also specifies that the Form 6-K, including the financial statements and MD&A but excluding the press release, is incorporated by reference into the company’s existing registration statements on Form S-8 and Form F-3, linking these updated results to previously registered securities.
Oculis Holding AG (OCS) is offering 4,691,358 ordinary shares at $20.25 per share and selling 740,740 shares in a concurrent registered direct offering. Underwriters have a 30‑day option to buy up to 703,703 additional shares.
The underwritten tranche reflects a $95.0 million gross raise with $5.7 million in underwriting commissions and $89.3 million proceeds before expenses. Across both transactions, Oculis estimates ~$102.5 million in net proceeds (or ~$115.5 million if the option is fully exercised). The company plans to fund and accelerate Privosegtor (OCS‑05) in acute optic neuritis (AON) and NAION, and for working capital and general corporate purposes.
Shares outstanding are expected to be 57,806,909 after the offering and concurrent sale (or 58,510,612 if the option is fully exercised), based on 52,374,811 shares outstanding as of September 30, 2025. Settlement is expected on a T+2 basis. The ordinary shares trade on Nasdaq and Nasdaq Iceland under “OCS.”
Oculis Holding AG is offering 740,740 ordinary shares at $20.25 per share in a registered direct sale to an investor. The company will receive $14,999,985 in gross proceeds, with estimated expenses of about $150,000.
The company is also conducting a concurrent underwritten offering of 4,691,358 shares, with an option for underwriters to buy up to 703,703 additional shares. Oculis estimates combined net proceeds of approximately $102.5 million (or $115.5 million if the option is fully exercised) to advance Privosegtor (OCS-05) in AON and NAION and for working capital and general corporate purposes.
Shares outstanding are expected to be 57,806,909 after this direct sale and the concurrent offering, based on 52,374,811 outstanding as of September 30, 2025. The company also terminated its prior $100 million ATM program with no shares sold.